Skip to main content
$6.74 -$0.11 (-1.6%)

04:30 PM EDT on 08/11/20

Precision Biosciences (NASDAQ:DTIL)

CAPS Rating: 5 out of 5

Current Price $6.74 Mkt Cap $355.3M
Open $6.87 P/E Ratio 0.00
Prev. Close $6.85 Div. (Yield) $0.00 (0.0%)
Daily Range $6.68 - $7.15 Volume 469,002
52-Wk Range $4.60 - $23.67 Avg. Daily Vol. 582,600

Caps

How do you think NASDAQ:DTIL will perform against the market?

Add Stock to CAPS Watchlist

All Players

23 Outperform
0 Underperform
 

All-Star Players

12 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:DTIL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFBlacknGold (95.64)
Submitted November 22, 2019

From 06/11/19:"Investors interested in the potential of gene editing to significantly affect human healthcare might want to give Precision BioSciences a closer look. The business owns a proprietary platform that avoids some of the primary concerns… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:DTIL VS S&P 500 (SPY)

NASDAQ:DTIL Summary

Fools bullish on NASDAQ:DTIL are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about DTIL.

Recs

0
Member Avatar KBOKSOFT (81.45) Submitted: 2/9/2020 8:59:37 PM : Outperform Start Price: $8.29 NASDAQ:DTIL Score: -19.19

Lottery Ticket

Recs

3
Member Avatar TMFBlacknGold (95.64) Submitted: 11/22/2019 11:52:22 AM : Outperform Start Price: $6.40 NASDAQ:DTIL Score: -5.94

From 06/11/19:

"Investors interested in the potential of gene editing to significantly affect human healthcare might want to give Precision BioSciences a closer look. The business owns a proprietary platform that avoids some of the primary concerns with CRISPR gene editing. And although ARCUS gene editing shares one key disadvantage with CRISPR, the company strategically focused initial clinical programs on allogeneic immunotherapies, which should give it a leg up in the competitive -- and potentially lucrative -- race. Throw in a unique pipeline in agricultural applications and sprinkle in the fact the company is flush with cash, and the $680 million gene-editing upstart might be worth the wait for long-term investors."

https://www.fool.com/investing/2019/06/11/is-the-newest-gene-editing-stock-a-buy.aspx

Recs

1
Member Avatar MattK520 (90.72) Submitted: 3/28/2019 11:30:05 AM : Outperform Start Price: $18.00 NASDAQ:DTIL Score: -81.29

Revolutionary gene editing technology, alternative to CRISPR

Leaderboard

Find the members with the highest scoring picks in DTIL.

Score Leader

bonjourmesamis

bonjourmesamis (79.44) Score: +65.77

The Score Leader is the player with the highest score across all their picks in DTIL.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
drugtrader 89.41 8/6/2020 Outperform 5Y $6.92 -2.53% +0.22% -2.75 0 Comment
Smiley81 < 20 10/28/2019 Outperform 5Y $6.30 +6.98% +9.88% -2.89 0 Comment
odocoileus 54.09 10/24/2019 Outperform 5Y $6.33 +6.56% +10.90% -4.34 0 Comment
TMFBlacknGold 95.64 10/23/2019 Outperform 5Y $6.40 +5.39% +11.33% -5.94 1 Comment
noSPORTSMANSHIP 99.85 4/7/2020 Outperform 3M $5.88 +14.63% +21.28% -6.66 0 Comment
PAGEBOY73 98.64 4/2/2020 Outperform 5Y $5.25 +28.38% +35.37% -6.99 0 Comment
BukzWildAF 78.89 4/13/2020 Outperform 1Y $6.35 +6.14% +20.01% -13.87 0 Comment
fiyah302 < 20 5/29/2020 Outperform 1Y $7.05 -4.40% +10.23% -14.63 0 Comment
wmtworker 78.53 4/1/2020 Outperform 5Y $5.87 +14.83% +32.96% -18.13 0 Comment
KBOKSOFT 81.45 2/10/2020 Outperform 5Y $8.29 -18.70% +0.49% -19.19 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for DTIL.